A fight by the U.S. Federal Trade Commission to make public a Georgia pharmaceutical company’s confidential memo detailing a strategy to pay rival drug companies not to compete has become part of a larger antitrust battle that has now reached the U.S. Supreme Court.
The FTC’s fight to unseal the memo is playing out in the lower courts even though the high court agreed last month to hear its long-running antitrust case against Marietta-based Solvay Pharmaceuticals Inc.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
